PS Ratio: 29.84

Basis: FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.

Is the P/S ratio high or low?

The P/S ratio of 29.84 is 23% above its estimated 2-year average of 24.30, near the low end of its estimated 2-year range (1.45–295.69).

As of 2026-10-06T16:22:39.035Z. 47.10% above its estimated 12-month average of 20.29.

GLUE PS Ratio Metrics

P/S vs. estimated history

At 29.84, P/S is near its estimated 2-year median — higher than 47% of readings in its estimated 2-year history.

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

Sales Valuation

PS Ratio Formula & Definition

PS Ratio = Market Cap / Revenue (TTM)

The price-to-sales ratio compares market capitalization to trailing revenue. It is useful for valuing companies with little or no earnings.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

PS Ratio FAQ

What is the P/S ratio for Monte Rosa Therapeutics, Inc. (GLUE)?

The P/S ratio for GLUE stock is 29.84.

Is Monte Rosa Therapeutics, Inc.'s P/S ratio high or low?

The P/S ratio of 29.84 is 23% above its estimated 2-year average of 24.30, near the low end of its estimated 2-year range (1.45–295.69).

What is the estimated TTM average P/S ratio for Monte Rosa Therapeutics, Inc. (GLUE)?

The estimated TTM average P/S ratio for GLUE stock is 20.29.

Showing the most recent 260 of 602 data points. The chart above shows the full history.

Related Metrics